Janux Therapeutics, Inc. · NASDAQ:JANX
Janux Therapeutics — Investor Presentation (November 2026)
20 slides from Janux Therapeutics's investor presentation, November 2026
Slide 1: Creating Transformative Medicines to Improve Patients' Lives
Creating Transformative Medicines to Improve Patients’ Lives November 2026
Slide 2: Forward-Looking Statements and Disclaimers
Forward-Looking Statements and Disclaimers This presentation includes certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking sta
Slide 3: JANX011 ARM Investor Update
JANX011 ARM Investor Update Human validation establishes JANX011 as an autoimmune asset and unlocks a broader platform opportunity November 2026
Slide 4: Three precision platforms create complementary value drivers across oncology and autoimmune disease
Three precision platforms create complementary value drivers across oncology and autoimmune disease TRACTr TRACIr ARM Oncology Foundation Oncology Franchise Amplifier Autoimmune Platform Tumor-activated T-cell engagement Localized CD28 co-stimulation Depletion of disease-driving autoimmune cells • D
Slide 5: One SC dose of JANX011 achieved deep B-cell depletion with Grade 1 only CRS
One SC dose of JANX011 achieved deep B-cell depletion with Grade 1 only CRS Phase 1 study in Healthy Normal Volunteers (HNV) INTEGRATED SINGLE DOSE HUMAN PROFILE One 3,000 µg SC administration | No step-up dosing >90% B-CELL DEPLETION GRADE 1 ONLY CRS Most subjects at 3,000 µg; two with undetectable
Slide 6: ARM is designed to combine deep B-cell depletion with the convenience of antibodies
ARM is designed to combine deep B-cell depletion with the convenience of antibodies CD19 CAR-T Drug free responses >1 year in some patients One time treatment, lymphodepletion, manufacturing and CRS/ICANS Durability of Response CAR-T ARM CD19-TCE Clinical activity established, durability depends upo
Slide 7: A selective TRBV6 binder is designed to balance efficacy, safety and immune preservation
A selective TRBV6 binder is designed to balance efficacy, safety and immune preservation TRBV6 Selective T-cell Binding CD19 Target Cell Binding • Proprietary domain binds the TCR β-variable • Broad B-cell coverage is intended to support region of TRBV6 rather than CD3 deep depletion and immune rese
Slide 8: Completed HNV study defines the starting dose range for JANX011 AID studies
Completed HNV study defines the starting dose range for JANX011 AID studies STUDY DESIGN | 4-6 subjects per cohort STUDY RESULTS ESCALATING SINGLE SC DOSE LEVELS ACTIVE DOSE RANGE Identified doses associated with meaningful B-cell depletion 3,000 µg 1,000 µg PERSISTENCE B-cell depletion observed bey
Slide 9: One 3,000 µg SC dose achieved deep B-cell depletion with Grade 1 only CRS
One 3,000 µg SC dose achieved deep B-cell depletion with Grade 1 only CRS Two subjects reached undetectable peripheral B-cell levels DOSE RESPONSE AND PERSISTENCE (n) 3,000µg | 2/5 subjects with undetectable B-cells 30 µg (6) Mean Change in B Cell Count (%) 100% 100 µg (6) 0% % Change in B Cell Coun
Slide 10: CRS was Grade 1 only with limited inflammatory cytokine induction
CRS was Grade 1 only with limited inflammatory cytokine induction 30-300 µg 1,000 µg 3,000 µg CRS EVENTS n=16 n=4 n=5 Grade 1 only 0 CRS events 1 Grade 1 event 4 Grade 1 events Peak IL-6 Peak TNFα Peak IFNƳ Peak IL-2 1000 1000 100 100 0.03 mg (6) Plasma Conc. (pg/mL) Plasma Conc. (pg/mL) Plasma Conc
Slide 11: No serious AEs or dose limiting toxicities were observed across cohorts
No serious AEs or dose limiting toxicities were observed across cohorts Observed events were predominantly Grade 1 and transient Treatment related adverse events by cohorts Highlights Cohort 1 Cohort 2 Cohort 3 Cohort 4 Cohort 5 Event (n=6) (n=6) (n=4) (n=4) (n=5) 0 Serious AEs or dose limiting toxi
Slide 12: Dose responsive, TRBV6 selective activation provides human validation of ARM mechanism
Dose responsive, TRBV6 selective activation provides human validation of ARM mechanism Similar subset and activation profiles for CD4 and CD8 T-cells TRBV6+ subset prevalence Selective TRBV6+ T-cell engagement in HNV Study HNV Study Samples AID PBMCs Mean CD25+ of CD8+ TRBV6- Tn (%) Mean CD25+ of CD
Slide 13: JANX011 achieved deep B-cell depletion after one SC dose with Grade 1 only CRS
JANX011 achieved deep B-cell depletion after one SC dose with Grade 1 only CRS Conventional CD19-TCEs require more intensive dosing, with Grade 2+ CRS reported JANX011 | SINGLE DOSE HUMAN PROFILE One 3,000 µg SC administration | No step-up dosing >90% B-CELL DEPLETION GRADE 1 ONLY CRS Most subjects
Slide 14: Scalable manufacturing and a low-volume SC formulation support broad development
Scalable manufacturing and a low-volume SC formulation support broad development Manufacturing and product development foundation SC formulation benchmark versus approved SC products 250 SCALABLE PROCESS Manufacturing process demonstrated at 500L clinical scale Concentration (mg/mL) 200 Belimumab Ef
Slide 15: JANX011 HNV data provides first human validation of the ARM platform
JANX011 HNV data provides first human validation of the ARM platform TARGET EXPANSION AUTOIMMUNE FRANCHISE Reusable Architecture Indication Breadth Apply ARM platform across B-cell Extend across diseases where B-cell targets and multi-specific formats depletion can drive value ARM PLATFORM DEVELOPME
Slide 16: JANX011 development strategy: establish human pharmacology, then expand by evidence
JANX011 development strategy: establish human pharmacology, then expand by evidence A focused path to early proof of concept and evidence gated autoimmune disease expansion HUMAN PHARMACOLOGY ESTABLISHED DEMONSTRATE PATIENT POC EXPAND BY EVIDENCE Completed HNV study Lead indications: ITP and RA Prio
Slide 17: Single dose HNV results establish a strong starting profile, not the ceiling
Single dose HNV results establish a strong starting profile, not the ceiling Step up and repeat dosing provide additional levers to improve tolerability and durability HNV | DEMONSTRATED STARTING PROFILE PATIENT STUDIES | REGIMEN OPTIMIZATION ONE 3,000 µg SC DOSE | NO STEP UP STEP UP DOSING Potentia
Slide 18: JANX011 combines near term autoimmune catalysts with ARM platform opportunity
JANX011 combines near term autoimmune catalysts with ARM platform opportunity FOCUSED EXECUTION PLATFORM LEVERAGE VALUE INFLECTIONS Establish autoimmune proof-of-concept Extend a validated ARM engine Generate sequential clinical and platform catalysts Initiate focused autoimmune studies Broaden the
Slide 19: Multiple clinical milestones across the three precision platforms
Multiple clinical milestones across the three precision platforms Program Stage 2H 2025 1H 2026 2H 2026 1H 2027 Updates Single-agent ✓ FPI in Phase 1b 1H 2027 TRACTr JANX007 Darolutamide ✓ FPI in Phase 1 2H 2027 PSMAxCD3 combo Single-agent FPI in Phase 2 TBA TRACTr JANX014 Dose ✓ FPI in Phase 1 TBA
Slide 20: David Campbell, Ph.D.
JanuxRx.com David Campbell, Ph.D. President and CEO 10955 Vista Sorrento Parkway San Diego, CA 92130 dcampbell@januxrx.com
Janux Therapeutics — Investor Presentation (November 2026) on 6ix